Header and Body 2

Problem Addressed

Many therapeutic agents in clinical development suffer from poor toxicity profiles. Thus, targeted delivery of therapeutic agents to avoid systemic toxicity has been an ongoing pursuit of interest. Attempts have been made towards targeted delivery by combining therapeutic agents with targeting agents, such as antibodies. Antibody-drug-conjugates (ADCs) have had some success but tend to be limited by the drug loading capacity and poor bio-distribution. This technology of antibody drug nanocarriers improves upon the drug loading capacity by 100-fold while also preserving the natural pharmacokinetics of antibodies.